Post Earnings Coverage as NeuroDerm Reported FY16 Results

Upcoming AWS Coverage on Biogen Post-Earnings Results

LONDON, UK / ACCESSWIRE / April 12, 2017 / Active Wall St. announces its post-earnings coverage on NeuroDerm Ltd. (NASDAQ: NDRM). The Company released its financial results for the fourth quarter fiscal 2016 (Q4 FY16) and full year 2016 (FY16) on March 30, 2017. The Rehovot, Israel-based pharmaceutical Company is a clinical-stage pharmaceutical Company with a limited operating history. It has not yet generated revenue from its operations and continues to incur significant research and development and other expenses related to its ongoing operations. Register with us now for your free membership at:

http://www.activewallst.com/register/

One of NeuroDerm’s competitors within the Biotechnology space, Biogen Inc. (NASDAQ: BIIB), announced on March 27, 2017, that it will report its Q1 2017 financial results on Tuesday, April 25, 2017, before the financial markets open. AWS will be initiating a research report on Biogen in the coming days.

Today, AWS is promoting its earnings coverage on NDRM; touching on BIIB. Get our free coverage by signing up to:

http://www.activewallst.com/register/

Earnings Reviewed

In Q4 FY16, NeuroDerm’s net expenditure on research and development were $9.52 million versus $4.13 million in the previous year’s same quarter. The Company attributed the rise in R&D expenses to an increase in subcontractors and materials, mainly from the ongoing clinical trials. Due to decrease in share-based compensation expenses, the Company’s general and administrative expenses fell to $1.66 million in Q4 FY16 from $2.04 million in the prior year’s comparable period.

The central nervous system (CNS) disorders drug-device combinations research Company’s operating loss increased during the reported quarter to $11.17 million from $6.17 million in Q4 FY15. Furthermore, the Company reported net loss of $11.10 million in Q4 FY16 compared to $6.73 million in Q4 FY15. Additionally, net loss per diluted share for Q4 FY16 stood at $0.49, which was higher than net loss per diluted share of $0.31 recorded in the year ago same period.

For the year ended December 31, 2016, NeuroDerm’s general and administrative expenses were $6.09 million compared to $5.16 million in the prior year. During FY16, the Company spent $27.01 million on net research and development expenses versus $12.81 million a year ago. The Company reported operating loss of $33.09 million in FY16 compared to operating loss of $17.97 million in FY15. Furthermore, NeuroDerm’s net loss had widened in FY16 to $32.50 million, or $1.48 loss per diluted share, from net loss of $15.61 million, or $0.82 loss per diluted share, in FY15.

Cash Flow & Balance Sheet

During Q4 FY16, net cash used in operating activities was $9.42 million compared to net cash used in operating activities of $4.63 million in last year’s comparable quarter. The Company had cash balance of $107.18 million as on December 31, 2016, compared to $84.74 million, at the close of books on December 31, 2015.

The Company has an accumulated deficit of $180.73 million as on December 31, 2016, compared to $148.24 million as on December 31, 2015. Furthermore, the Company’s activities are being funded through public and private offerings of the securities and issuance of convertible loans and warrants.

Stock Performance

On Tuesday, April 11, 2017, the stock closed the trading session at $25.75, marginally up 0.39% from its previous closing price of $25.65. A total volume of 121.55 thousand shares have exchanged hands. NeuroDerm’s stock price rallied 17.58% in the last three months, 35.53% in the past six months, and 72.47% in the previous twelve months. Moreover, the stock gained 15.99% since the start of the year. At Tuesday’s closing price, the stock’s net capitalization stands at $684.69 million.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 459573